Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Morinaga, Soichiro ^a   Nakamura, Yoshiyasu ^a   Watanabe, Takuo ^a   Mikayama, Hiroshi ^a   Tamagawa, Hiroshi ^a   Yamamoto, Naoto ^a   Shiozawa, Manabu ^a   Akaike, Makoto ^a   Ohkawa, Shinnichi ^a   Kameda, Yoichi ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; STAINING; TREATMENT OUTCOME; TUMOR CELL;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS;

EID: 84865021068     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2054-z     Document Type: Article

References (13)

1. MH Katz JB Fleming JE Lee PW Pisters 2010 Current status of adjuvant therapy for pancreatic cancer Oncologist. 15 1205 1213 21045189 10.1634/theoncologist.2010-0121 1:CAS:528:DC%2BC3MXht1Ghsbg%3D
2. H Oettle S Post P Neuhaus K Gellert J Langrehr K Ridwelski, et al. 2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA. 297 267 277 17227978 10.1001/jama.297.3.267 1:CAS:528: DC%2BD2sXotVCmug%3D%3D
3. P Neuhaus H Riess S Post 2008 Final results of the randomized, prospective, multicenter phase three trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer J Clin Oncol. 26 15 suppl LBA4504
4. WF Regine KA Winter RA Abrams H Safran JP Hoffman A Konski, et al. 2008 Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA. 299 1019 1026 18319412 10.1001/jama.299.9.1019 1:CAS:528:DC%2BD1cXjtVSltL0%3D
5. JP Neoptolemos DD Stocken C Bassi P Ghaneh D Cunningham D Goldstein, et al. 2010 Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA. 304 1073 1081 20823433 10.1001/jama.2010.1275 1:CAS:528: DC%2BC3cXhtFequ7nE
6. JR Mackey RS Mani M Selner D Mowles JD Young JA Belt, et al. 1998 Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 58 4349 4357 9766663 1:CAS:528:DyaK1cXmsVyqsbo%3D
7. J Garcia-Manteiga M Molina-Arcas FJ Casado A Mazo M Pastor-Anglada 2003 Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′, 2′-difluorodeoxycytidine- induced cytotoxicity Clin Cancer Res. 9 5000 5008 14581375 1:CAS:528:DC%2BD3sXosVGjtbw%3D
8. VL Damaraju S Damaraju JD Young SA Baldwin J Mackey MB Sawyer, et al. 2003 Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy Oncogene. 22 7524 7536 14576856 10.1038/sj.onc.1206952 1:CAS:528:DC%2BD3sXotlaju7k%3D
9. E Giovannetti MT Del V Mey N Funel S Nannizzi S Ricci, et al. 2006 Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res. 66 3928 3935 16585222 10.1158/0008-5472.CAN-05-4203 1:CAS:528:DC%2BD28XjtVOqs7k%3D
10. J Spratlin R Sangha D Glubrecht L Dabbagh JD Young C Dumontet, et al. 2004 The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res. 10 6956 6961 15501974 10.1158/1078-0432.CCR-04- 0224 1:CAS:528:DC%2BD2cXpslGltbc%3D
11. JJ Farrell H Elsaleh M Garcia R Lai A Ammar WF Regine, et al. 2009 Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology. 136 187 195 18992248 10.1053/j.gastro.2008.09.067
12. R Marechal JR Mackey R Lai P Demetter M Peeters M Polus, et al. 2009 Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma Clin Cancer Res. 15 2913 2919 19318496 10.1158/1078-0432.CCR-08-2080 1:CAS:528:DC%2BD1MXksV2nt7o%3D
13. JR Mackey LL Jennings ML Clarke CL Santos L Dabbagh M Vsianska, et al. 2002 Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers Clin Cancer Res. 8 110 116 11801546 1:CAS:528:DC%2BD38XhsVKmtb4%3D